Nogapendekin Alfa Inbakicept-pmln
(noh-GAP-en-DEH-kin AL-fuh in-BAK-ih-sept)
This page contains brief information about nogapendekin alfa inbakicept-pmln and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.
US Brand Name(s)
Anktiva
FDA Approved
Yes
FDA label information for this drug is available at DailyMed.
Use in Cancer
Nogapendekin alfa inbakicept-pmln is approved to treat:
- Non-muscle–invasive bladder cancer with carcinoma in situ, with or without papillary tumors. It is used with bacillus Calmette-Guérin (BCG) in adults whose cancer does not respond to treatment with BCG alone.
Nogapendekin alfa inbakicept-pmln is also being studied in the treatment of other types of cancer.
More About Nogapendekin Alfa Inbakicept-pmln
Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.
Research Results and Related Resources
Clinical Trials Accepting Patients
Find Clinical Trials for Nogapendekin Alfa Inbakicept-pmln - Check for trials from NCI's list of cancer clinical trials now accepting patients.